We are live on
!
Find out more
EA
Emerald Advisers Portfolio holdings
AUM
$3.16B
1-Year Est. Return
109.58%
This Fund
S&P 500
This Quarter
Est. Return
+36.72%
1 Year Est. Return
+109.58%
3 Year Est. Return
+352.93%
5 Year Est. Return
+451.34%
10 Year Est. Return
+3,577.15%
AUM
$3.01B
AUM Growth
+$583M
(+24%)
Cap. Flow
-$32.3M
Cap. Flow
% of AUM
-1.07%
Top 10 Holdings %
Top 10 Hldgs %
19.61%
Holding
374
New
40
Increased
94
Reduced
116
Closed
88
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
+$26.9M |
| 2 |
Eastern Bankshares
EBC
|
+$24.9M |
| 3 |
MediaAlpha
MAX
|
+$21.2M |
| 4 |
Houlihan Lokey
HLI
|
+$19.7M |
| 5 |
Allegro MicroSystems
ALGM
|
+$18.9M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$43.8M |
| 2 |
BLD
TopBuild
BLD
|
+$38.3M |
| 3 |
Twist Bioscience
TWST
|
+$28.8M |
| 4 |
QTS
QTS REALTY TRUST, INC.
QTS
|
+$25M |
| 5 |
PS
Pluralsight, Inc. Class A Common Stock
PS
|
+$24.1M |
Sector Composition
| 1 | Healthcare | 23.28% |
| 2 | Technology | 20.52% |
| 3 | Consumer Discretionary | 15.17% |
| 4 | Industrials | 13.7% |
| 5 | Financials | 8.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Chegg
CHGG
$91.4M
| $73.8M | 2.45% |
816,648
-71,100
| -8% | -$5.65M |
|
2
NeoGenomics
NEO
$1.9B
| $72.7M | 2.41% |
1,350,805
-14,551
| -1% | -$658K |
|
3
Freshpet
FRPT
$2.78B
| $70.1M | 2.33% |
493,933
-169,270
| -26% | -$21.8M |
|
4
Rapid7
RPD
$815M
| $62.6M | 2.08% |
694,335
+1,098
| +0.2% | +$78.5K |
|
5
Varonis Systems
VRNS
$5.46B
| $60.5M | 2.01% |
1,109,406
-181,887
| -14% | -$7.89M |
|
6
MACOM Technology Solutions
MTSI
$20.4B
| $52.3M | 1.74% |
950,485
+1,890
| +0.2% | +$80.6K |
|
7
Kratos Defense & Security Solutions
KTOS
$8.63B
| $51.3M | 1.7% |
1,868,519
-284,015
| -13% | -$6.22M |
|
8
Churchill Downs
CHDN
$5.85B
| $51.1M | 1.7% |
524,538
-156,382
| -23% | -$14.2M |
|
9
Simply Good Foods
SMPL
$980M
| $48.7M | 1.62% |
1,552,968
-178,045
| -10% | -$4.14M |
|
10
Chart Industries
GTLS
| $47.7M | 1.58% |
405,175
+2,141
| +0.5% | +$207K |
|
11
Trex
TREX
$4.69B
| $44.4M | 1.47% |
530,706
-1,472
| -0.3% | -$113K |
|
|
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $43.5M | 1.44% |
357,038
+58,030
| +19% | +$6.36M |
|
|
BWIN
13
Baldwin Insurance Group
BWIN
$2.66B
| $42M | 1.39% |
1,399,733
+176,659
| +14% | +$5.11M |
|
14
Tetra Tech
TTEK
$8.2B
| $41.9M | 1.39% |
1,810,595
-114,880
| -6% | -$2.59M |
|
15
Moelis & Co
MC
$5.02B
| $38.7M | 1.28% |
827,636
+12,786
| +2% | +$514K |
|
16
Jack in the Box
JACK
$286M
| $38.1M | 1.26% |
410,115
+2,445
| +0.6% | +$214K |
|
|
SAIL
17
DELISTED
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
| $37.7M | 1.25% |
707,471
-800
| -0.1% | -$37.5K |
|
18
TriNet
TNET
$2.74B
| $35.4M | 1.17% |
438,960
+73,085
| +20% | +$5.4M |
|
|
MNTV
19
DELISTED
Momentive Global Inc. Common Stock
MNTV
| $35.4M | 1.17% |
1,384,164
-4,746
| -0.3% | -$107K |
|
|
PPBI
20
DELISTED
Pacific Premier Bancorp
PPBI
| $34.7M | 1.15% |
1,107,907
+42,153
| +4% | +$1.17M |
|
21
Replimune Group
REPL
$859M
| $33.7M | 1.12% |
882,464
-9,297
| -1% | -$387K |
|
22
Palomar
PLMR
$3.59B
| $33.6M | 1.11% |
378,082
-49,477
| -12% | -$4.16M |
|
|
BPMC
23
DELISTED
Blueprint Medicines
BPMC
| $33.4M | 1.11% |
297,905
-82,684
| -22% | -$8.71M |
|
24
BellRing Brands
BRBR
$1.41B
| $33.3M | 1.11% |
1,370,195
-215,707
| -14% | -$4.69M |
|
25
New Fortress Energy
NFE
$102M
| $33M | 1.09% |
615,133
-133,163
| -18% | -$6.1M |
|
Similar funds
AWE
FTUS
BFA
BP
CVA
DWP
GKWIM
BI
Emerald Advisers's Q4 2020 Portfolio in Review
As of Q4 2020, Emerald Advisers held 374 positions worth $3.01B, up 24% from $2.43B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Emerald Advisers's Q4 2020 filing shows 40 new, 94 increased, 116 reduced and 88 closed positions. Its largest new stake was Ultragenyx Pharmaceutical: 226,875 shares worth $31.4M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $43.8M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Discretionary.
- Emerald Advisers's largest Q4 2020 buy was Ultragenyx Pharmaceutical: 226,875 shares worth $31.4M.
- Emerald Advisers added most to Arena Pharmaceuticals Inc in Q4 2020, an estimated $18.6M increase.
- Emerald Advisers's biggest Q4 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $43.8M.
- Emerald Advisers fully exited Pluralsight, Inc. Class A Common Stock in Q4 2020, selling an estimated $24.1M.
- Emerald Advisers's ten largest holdings make up 20% of its $3.01B portfolio in Q4 2020.
- Emerald Advisers opened 40 new positions and closed 88 in Q4 2020.
- Emerald Advisers's portfolio value rose 24% quarter-over-quarter to $3.01B.
Based on Emerald Advisers's 13F filing for Q4 2020, filed 29 Jan 2021.